President-elect Donald Trump promised to cut FDA regulations and accelerate drug approvals, and some critics of the agency say its approval authority should be revoked and the agency should be privatized, writes Joseph Gulfo of the Lewis Center for Healthcare Innovation and Technology at Fairleigh Dickinson University. “The better answer is to make two practical changes that can quickly help speed up drug approvals and also lower drug prices by reducing development costs and increasing competition,” Gulfo writes